8-K: Spruce Biosciences Receives Nasdaq Non-Compliance Notice Due to Low Share Price

Spruce Biosciences has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, as its stock price has fallen below $1.00 for 30 consecutive days.

Summary

• Spruce Biosciences received a notice from Nasdaq on April 26, 2024, stating that the company is not in compliance with Nasdaq's Listing Rule 5450(a)(1).
• The non-compliance is due to the company's common stock price falling below $1.00 per share for 30 consecutive business days.
• This notification does not immediately affect the listing or trading of Spruce Biosciences' stock on the Nasdaq Global Select Market.
• Spruce Biosciences has 180 calendar days, until October 23, 2024, to regain compliance by having its stock price meet or exceed $1.00 for at least ten consecutive business days.
• If the company fails to regain compliance by October 23, 2024, it may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
• To qualify for the additional period, the company must meet all other initial listing standards for the Nasdaq Capital Market, except for the bid price requirement.
• Failure to regain compliance during the second period could result in the delisting of Spruce Biosciences' stock.
• The company intends to monitor its stock price and consider options to regain compliance, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (non-compliance notice) and uncertainty about the company's ability to regain compliance, leading to a low sentiment score.

Positives

• The notification does not immediately affect the listing or trading of the company's stock.
• The company has a 180-day grace period to regain compliance.
• An additional 180-day compliance period is possible by transferring to the Nasdaq Capital Market.

Negatives

• The company's stock price has fallen below the minimum bid price requirement of $1.00 for 30 consecutive business days.
• There is no guarantee that the company will be able to regain compliance with Nasdaq's listing rules.
• Failure to regain compliance could result in the delisting of the company's stock.

Risks

• The company's stock price may not recover to above $1.00 within the given time frame.
• The company may not meet the requirements for transferring to the Nasdaq Capital Market.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.

Future Outlook

The company intends to actively monitor its stock price and consider available options to regain compliance with the listing requirements, but there is no assurance of success.

Management Comments

• The company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirements.

Industry Context

This type of non-compliance notice is not uncommon for companies experiencing stock price declines, particularly in the biotechnology sector, which can be volatile. Other companies in the sector may face similar challenges if their stock prices fall below the minimum bid price.

Comparison to Industry Standards

• Many small-cap biotech companies face the risk of delisting due to low stock prices, especially during periods of market volatility or negative clinical trial results.
• Companies like Agenus Inc. (AGEN) and Cassava Sciences (SAVA) have also faced similar challenges with maintaining Nasdaq listing requirements.
• The 180-day grace period is a standard procedure for Nasdaq-listed companies facing non-compliance issues.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the stock price decrease and potential delisting.
• Employees may be concerned about the company's future prospects.
• Creditors may become more cautious about lending to the company.

Next Steps

• The company will actively monitor its stock price.
• The company will consider available options to regain compliance with Nasdaq listing requirements.
• The company may need to transfer to the Nasdaq Capital Market if it cannot regain compliance within the initial 180-day period.

Key Dates

Keywords

Nasdaq, delisting, compliance, minimum bid price, stock price, SPRB, Spruce Biosciences